SEQENS
integrated pharma specialty ingredients
- B2B
- Has physical offices
- Manufacturing
- Sales-led purchase
About SEQENS
Worldwide leader pharmaceutical solutions, specialty ingredients. Operates manufacturing sites, R&D centers. Offers broad portfolio active ingredients, intermediates, specialty ingredients.
Key facts
- Industry
- Pharmaceutical Manufacturing
- Company size
- 1,001–5,000 employees
- Headquarters
- Écully, Auvergne-Rhône-Alpes, France
- Founded
- 2003
- Revenue
- $71.9M – $568MTamtam estimate
- SIREN
- 444465736
- Website
- seqens.com
- linkedin.com/company/seqens
Jobs at SEQENS
- Responsable Ressources Humaines Multi-sites H/F
- Technicien EIA H/F
- Alternance - 24 mois - Opérateur de Production 5x8 H/F H/F
- Alternance 12 mois – Opérateur production H/F
- Alternance - Technicien de Maintenance H/F (24 mois) H/F
- Production Worker H/F
- Chargé(e) Assurance Qualité Qualification/Validation H/F
- Production Worker M/F/D
SEQENS in the news
- Latham & Watkins Advises SEQENS on Its Financial Restructuring
SEQENS, advised by Latham & Watkins, is undergoing a financial restructuring to create a more sustainable capital structure, leading to senior lenders becoming shareholders.
- Latham & Watkins Advises SEQENS on Its Financial Restructuring
Latham & Watkins advised SEQENS on a financial restructuring that will result in senior lenders becoming new shareholders to support the company's long-term development.
- Médicaments : l'usine de Seqens dédiée au paracétamol fragilisée par le contexte géopolitique
A proposed paracetamol price cut in France threatens the profitability of Seqens' new 120-million-euro production facility, which aims to supply half of Europe's needs.
- SEQENS Senior Lenders to Assume Majority Ownership Following Financial Restructuring
SEQENS's senior lenders will assume majority ownership as part of a financial restructuring, with various law firms advising the involved parties.
- Seqens active un lender-led
Seqens, a pharmaceutical ingredient supplier, is undergoing a lender-led restructuring five years after its LBO due to the chemical industry's structural crisis.
SEQENS at a glance
SEQENS is a B2B company in the Pharmaceutical Manufacturing industry, headquartered in Écully, Auvergne-Rhône-Alpes, France.
SEQENS was founded in 2003.
SEQENS has 1,001–5,000 employees.
SEQENS's revenue is $71.9M – $568M (Tamtam estimate).
SEQENS's SIREN number is 444465736.
SEQENS is hiring: 8 recent open roles, including Responsable Ressources Humaines Multi-sites H/F, Technicien EIA H/F, Alternance - 24 mois - Opérateur de Production 5x8 H/F H/F.
Selling to companies like SEQENS?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies